UTHR: Q2 2026 revenue was $783M, with record Tyvaso DPI growth and strong pipeline progress
I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue reached $783M, down 2% year-over-year, with strong growth in Unituxin and record Tyvaso DPI patient metrics. Late-stage clinical successes for Tyvaso in IPF and ralinepag in PAH support a robust pipeline and regulatory momentum.Original document: United Therapeutics Corporation [UTHR] Slides Release — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue reached $783M, down 2% year-over-year, with strong growth in Unituxin and record Tyvaso DPI patient metrics. Late-stage clinical successes for Tyvaso in IPF and ralinepag in PAH support a robust pipeline and regulatory momentum.
Original document: United Therapeutics Corporation [UTHR] Slides Release — Aug. 5 2026